基于加权TOPSIS法的注射用英夫利西单抗药物利用评价  

Evaluation of drug use of Infliximab for injection based on weighted TOPSIS method

作　　者：程赛赛 朱峰[2] 周碧 CHENG Saisai;ZHU Feng;ZHOU Bi(Department of Pharmacy,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou 234000,China;Department of Pediatrics,Suzhou Hospital Affiliated to Anhui Medical University,Suzhou 234000,China)

机构地区：[1]安徽医科大学附属宿州医院药剂科,安徽宿州234000 [2]安徽医科大学附属宿州医院儿科,安徽宿州234000

出　　处：《现代药物与临床》2025年第2期463-468,共6页Drugs & Clinic

基　　金：安徽省临床医学研究转化专项项目(202304295107020119)。

摘　　要：目的通过构建注射用英夫利西单抗的药物利用评价(DUE)标准,促进注射用英夫利西单抗的临床合理应用。方法使用属性层次模型(AHM)结合逼近理想解排序(TOPSIS)法,对安徽医科大学附属宿州医院2023年1月—2024年12月共197例患者的注射用英夫利西单抗临床使用情况进行合理性评价。结果评价的197例病例中,完全合理的有16例,占比8.12%;合理的有54例,占比27.41%;基本合理的有99例,占比50.25%;不合理的有28例,占比14.21%。结论安徽医科大学附属宿州医院注射用英夫利西单抗的临床应用基本合理,但在适应证、输液反应及处理、病程记录、禁忌证、注意事项、不良反应处理及监测等方面存在较高的不合理率。建立的英夫利西单抗的DUE标准,可用于临床合理用药的评价。Objective To promote the rational clinical use of Infliximab for injection by establishing the DUE criteria for Infliximab for injection.Methods AHM combined with TOPSIS method was used to evaluate the rationality of Infliximab for injection in 197 patients in Suzhou Hospital Affiliated to Anhui Medical University from January 2023 to December 2024.Results Among 197 cases evaluated,16 cases were completely reasonable,accounting for 8.12%,54 cases were reasonable,accounting for 27.41%,99 cases were basically reasonable,accounting for 50.25%.There were 28 cases of unreasonable,accounting for 14.21%.Conclusion The clinical application of Infliximab for injection in Suzhou Hospital Affiliated to Anhui Medical University is basically reasonable,but there are high unreasonable rates in indications,infusion reactions and treatment,course records,contraindications,precautions,treatment and monitoring of adverse reactions.The established DUE criteria for Infliximab for injection can be used to evaluate the rational use of infliximab in clinical practice.

关 键 词：注射用英夫利西单抗 药物利用评价 合理用药 逼近理想解排序法 属性层次模型 

分 类 号：R979.5[医药卫生—药品]